| Browse All

Ocular Therapeutix, Inc. (OCUL)

Healthcare | Biotechnology | Bedford, United States | NasdaqGM
9.82 USD +0.96 (10.835%) ⇧ (April 17, 2026, 4 p.m. EDT)
After hours: 9.80 -0.02 (-0.020%) ⇩ (April 17, 2026, 7:13 p.m. EDT)

Short-term: ★★★☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 19, 2026, 12:55 a.m. EDT

Despite analyst 'Strong Buy' ratings, the fundamentals are severely distressed with negative revenue growth (-22.4%), negative gross and operating margins, and a negative free cash flow. The stock has recently reversed a prior decline to reset near recent lows, but the lack of a dividend and deteriorating economic metrics keep it in the 'weak' long-term category until revenue profitability is proven.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
MSTL ✓0.180144
AutoARIMA0.207442
AutoETS0.207442
AutoTheta0.234642

Forecast horizon: 45 days | Selected: MSTL

Forecast Reliability
Score 80%
H-stat 0.95
Ljung-Box p 0.000
Jarque-Bera p 0.985
Excess Kurtosis 0.09
Attribute Value
Sector Healthcare
Debt to Equity Ratio 11.763
Revenue per Share 0.277
Market Cap 2,137,733,120
Forward P/E -7.82
Beta 0.95
Website https://www.ocutx.com

As of April 19, 2026, 12:55 a.m. EDT: Options market shows heightened volatility risk with premium implicit volatility (IV) spikes at low strikes (e.g., $1 OTM for calls, $2.5 for puts) indicating a need for volatility insurance against significant price moves. Open Interest (OI) walls are prominent near the current price ($10–$12 strike), with call OI exceeding put OI in June and September, suggesting speculative bullish positioning for upside, though sell warrants in lower-dated weeks remain hidden in the data.


Info Dump

Attribute Value
52 Week Change 0.2904073
Address1 15 Crosby Drive
All Time High 44.19
All Time Low 1.995
Ask 9.85
Ask Size 8
Audit Risk 5
Average Analyst Rating 1.4 - Strong Buy
Average Daily Volume10 Day 3,507,300
Average Daily Volume3 Month 5,803,138
Average Volume 5,803,138
Average Volume10Days 3,507,300
Beta 0.952
Bid 9.79
Bid Size 8
Board Risk 7
Book Value 3.03
City Bedford
Compensation As Of Epoch Date 1,735,603,200
Compensation Risk 10
Country United States
Crypto Tradeable 0
Currency USD
Current Price 9.82
Current Ratio 15.394
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 9.86
Day Low 9.01
Debt To Equity 11.763
Display Name Ocular Therapeutix
Earnings Call Timestamp End 1,762,261,200
Earnings Call Timestamp Start 1,762,261,200
Earnings Timestamp 1,770,298,200
Earnings Timestamp End 1,777,984,200
Earnings Timestamp Start 1,777,984,200
Ebitda -265,694,000
Ebitda Margins 0.0
Enterprise To Ebitda -5.561
Enterprise To Revenue 28.443
Enterprise Value 1,477,641,216
Eps Current Year -1.3975
Eps Forward -1.256
Eps Trailing Twelve Months -1.42
Esg Populated 0
Exchange NGM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 8.8249
Fifty Day Average Change 0.9951
Fifty Day Average Change Percent 0.11276049
Fifty Two Week Change Percent 29.04073
Fifty Two Week High 16.44
Fifty Two Week High Change -6.620001
Fifty Two Week High Change Percent -0.40267643
Fifty Two Week Low 6.23
Fifty Two Week Low Change 3.5899997
Fifty Two Week Low Change Percent 0.57624394
Fifty Two Week Range 6.23 - 16.44
Financial Currency USD
First Trade Date Milliseconds 1,406,295,000,000
Float Shares 215,406,015
Forward Eps -1.256
Forward P E -7.818471
Free Cashflow -128,276,496
Full Exchange Name NasdaqGM
Full Time Employees 325
Gmt Off Set Milliseconds -14,400,000
Governance Epoch Date 1,775,001,600
Gross Margins -2.92043
Gross Profits -151,719,008
Has Pre Post Market Data 1
Held Percent Insiders 0.01359
Held Percent Institutions 0.90299004
Implied Shares Outstanding 217,691,779
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Long Name Ocular Therapeutix, Inc.
Market us_market
Market Cap 2,137,733,120
Market State CLOSED
Max Age 86,400
Message Board Id finmb_41955650
Most Recent Quarter 1,767,139,200
Net Income To Common -265,939,008
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 2,137,733,269
Number Of Analyst Opinions 11
Open 9.01
Operating Cashflow -204,883,008
Operating Margins -5.26491
Overall Risk 10
Payout Ratio 0.0
Phone 781 357 4000
Post Market Change -0.019999504
Post Market Change Percent -0.20366095
Post Market Price 9.8
Post Market Time 1,776,467,636
Previous Close 8.86
Price Eps Current Year -7.026833
Price Hint 2
Price To Book 3.2409241
Price To Sales Trailing12 Months 41.14903
Profit Margins 0.0
Quick Ratio 15.111
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key strong_buy
Recommendation Mean 1.36364
Region US
Regular Market Change 0.96
Regular Market Change Percent 10.8352
Regular Market Day High 9.86
Regular Market Day Low 9.01
Regular Market Day Range 9.01 - 9.86
Regular Market Open 9.01
Regular Market Previous Close 8.86
Regular Market Price 9.82
Regular Market Time 1,776,456,000
Regular Market Volume 5,316,554
Return On Assets -0.26661
Return On Equity -0.54852
Revenue Growth -0.224
Revenue Per Share 0.277
Sand P52 Week Change 0.38150132
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Share Holder Rights Risk 7
Shares Outstanding 217,691,779
Shares Percent Shares Out 0.1157
Shares Short 25,192,853
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 17,648,381
Short Name Ocular Therapeutix, Inc.
Short Percent Of Float 0.1161
Short Ratio 5.04
Source Interval 15
State MA
Symbol OCUL
Target High Price 34.0
Target Low Price 18.0
Target Mean Price 26.0
Target Median Price 27.0
Total Cash 737,059,968
Total Cash Per Share 3.386
Total Debt 76,968,000
Total Revenue 51,951,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -1.42
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 11.09935
Two Hundred Day Average Change -1.2793503
Two Hundred Day Average Change Percent -0.11526353
Type Disp Equity
Volume 5,316,554
Website https://www.ocutx.com
Zip 1,730